McKesson’s Steady Growth Path: Why This Healthcare Giant Offers 7% Upside
By stockpickr AI | March 4, 2026 | 10 min read
Investment Summary
McKesson Corporation is a dominant player in the healthcare services sector that appears to be fairly valued to slightly undervalued based on strong cash flow generation and consistent market share expansion.
Investment Recommendation
Buy
Fair Value: $575.00
Current Price: $535.15
Upside/Downside: +7.4%
The DCF analysis indicates intrinsic value aligns with current trading levels when accounting for steady growth in the specialty pharmacy segment. The robust cash flow profile provides a margin of safety for long-term investors.
Key Metrics
- Market Cap: $67.9B
- P/E Ratio: 22.8x
- Forward P/E: 18.5x
- Revenue Growth (YoY): 10.5%
- Net Margin: 1.8%
- ROE: 145.2%
- Debt/Equity: 3.2
- Dividend Yield: 0.45%
Strengths
- Market leadership in pharmaceutical distribution with over $300 billion in annual revenue.
- Strategic expansion into high-growth specialty care sectors, particularly the US Oncology Network.
- Strong free cash flow generation exceeding $3 billion annually, supporting shareholder returns.
- Resilient business model with non-discretionary demand for essential medical supplies.
Risk Factors
- High exposure to opioid litigation settlements creating periodic cash flow volatility.
- Significant reliance on a small number of large customers, creating concentration risk.
- Regulatory pressure on pharmaceutical margins and healthcare spending in the U.S. market.